Sai Parenterals is a pharmaceutical formulator that, through its consolidated entity with Noumed, develops, registers and supplies injectable and other dosage products, mainly to pharmacy chains in Australia and New Zealand, while also running a CDMO export business and an Indian branded formulations business. The money is made by owning intellectual property and market authorisations rather than by selling commodity pills: Noumed holds 451 IP dossiers and has 5 exclusive long-term contracts plus 10 exclusive molecule contracts covering 526 SKUs, with the two largest pharmacy chain groups reaching more than 2,900 of Australia's 5,500 pharmacies. In July 2026 one exclusive OTC supply agreement was renewed for 7.5 years, valued at 202 million AUD, roughly 1,300 crore, with built-in annual additions of 12 new products. Consolidated FY26 revenue was 381 crore with 47 crore EBITDA, and Q1 FY27 gross margin improved to 41.8% from 38.1% in Q4 FY26, while consolidated EBITDA margin was 14.9% and standalone India EBITDA margin was about 29%. That combination of moderate consolidated margin and high standalone margin captures the current drag from outsourced manufacturing in Australia and the latent profitability of the in-house model.
The moat is regulatory and relational, not scale-driven. Noumed owns the registrations and IP; pharmacy chains own their brands but depend on Noumed for market authorisation, inventory, logistics, distribution, pharmacovigilance and regulatory support. Contracts run 5-plus years with product-wise annual volume forecasts, and actual offtake has been running ahead of forecasts. TGA approval is a barrier to entry, and Noumed's 451 dossiers compress launch timelines from 18-24 months to 6-9 months, a timing advantage that matters when pharmacy buyers are choosing exclusive partners. The renewed Ebos agreement is exclusive for 7.5 years, and the company also supplies through Wesfarmers Health, giving two privileged channel relationships in a market where the top two networks cover just over half of Australian pharmacies. The Australian government's 20 million AUD Modern Manufacturing grant for the Adelaide facility further acknowledges the sovereign capacity value of local manufacturing. This is not a standard commodity generics business: the combination of owned dossiers, TGA-qualified assets and long-term exclusive supply makes switching costly for customers and gives the economics duration.
The inflection is asset commissioning. At the time of the August 2026 call, the Adelaide facility physical completion was targeted for January 2027, TGA licensing inspection by 31 March 2027 and safe-run manufacturing in April 2027. In India, the Saikriti Pharma project is being built to EU GMP and US FDA standards with roughly 154.66 million units of injectable capacity against about 105 million units in the original plan, a 47% uplift, with completion targeted April 2027. The proposed acquisition of the Karthik Laboratories R&D centre, expected to close by 30 September 2026, adds 150 SKUs across 86 molecules, including lyophilised, liposomal and oncology injectables. By 18-24 months from now, these assets should be running, the 67 dossiers under development will have been commercialised across FY27 and FY28, and local manufacturing in Adelaide should replace part of the Indian contract manufacturing network, reducing mandatory inventory holding from 9-10 months to around 5-6 months. At that point the FY27 revenue target of 750 crore at 17% EBITDA margin should become the base, not the ceiling, because the new capacity is being commissioned into exclusive, multi-year contracts with committed new product lists.
Management has been consistent across the May 2026 and August 2026 calls. It promised FY27 revenue of 750 crore at around 17% EBITDA margin, TGA approval by 31 March 2027, and a peak debt year in FY27 followed by deleveraging from FY28. On the latest call it reiterated all of those targets and added that Q1 FY27 revenue represented roughly 24% of the full-year target, ahead of the expected second-half-weighted pace, and that EBITDA margin had improved 50 basis points sequentially to 14.9% despite elevated air freight costs. Gross margin expanded 370 basis points, and standalone India EBITDA rose to about 29% from 20% a year earlier, evidence that operating leverage is already visible where assets are not being commissioned. Debt was 310 crore at 30 June 2026 versus 319 crore at March 2026, cash was 184 crore, and debt-to-equity was 0.6 times. The capital allocation story is a 440 crore growth capex programme, with India expansion and R&D partly IPO-funded, the Australian facility funded with a 20 million AUD grant and debt, and the balance sheet intended to start deleveraging in FY28 once the assets contribute cash flow.
The quantified earnings path is therefore: Q1 FY27 already operating at an annualised revenue pace above the quarterly requirement, FY27 full-year guidance of 750 crore and 17% EBITDA, and FY28 with the Adelaide and Saikriti facilities contributing for almost the full year, the 67 dossiers commercialising, and inventory intensity falling. For that path to hold, the TGA licence must be received by 31 March 2027 and safe-run manufacturing must begin in April 2027; the first 12 new products under the Ebos agreement need to follow the cadence, and raw-material price recovery, after the 90-120 day lag, needs to complete over FY27. The single most important falsifier is any slip in the Adelaide timeline or in the TGA inspection, because that would delay the vertical integration that moves margins toward the 17% target and postpone the debt decline from FY28. The apparent tension between gross margin up 370 basis points and consolidated EBITDA at 14.9% versus 17% guidance is explained by one-off air freight costs and partial cost recovery, not by structural deterioration, and should unwind as price revisions flow and local manufacturing replaces external CMOs. The execution risk is real, but the business model and contracts give the thesis a clear cause and effect: if the facilities open as scheduled, the revenue and margin are already largely contracted.
companyname: Sai Parenterals Limited ticker: SAIPARENT sector: Pharmaceuticals (CDMO, OTC, Formulations) Sai Parenterals is an integrated pharmaceutical platform built around three growth engines: a CDMO export business, an Australian and New Zealand platform acquired with Noumed Pharmaceuticals, and a domestic branded formulation business. The company listed on Indian exchanges in FY26 and completed the Noumed acquisition on 12 November 2025. That acquisition changed the company's shape, movin...
Read the full report →capex, margin expansion, regulatory approval, acquisition inorganic
FY27 revenue guided at INR750 crores with 17% EBITDA margin driven by existing contracts, new dossier commercialization, and Noumed contribution
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Sai Parenterals Ltd and 4,900+ companies.
5-day free pass. No card required.